Agenus (AGEN) Competitors $1.67 +0.03 (+1.83%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.02 (+0.90%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. ACHV, LXRX, RGLS, DOMH, FBIO, CRIS, BOLT, SABS, MTEM, and AMGNShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Achieve Life Sciences (ACHV), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Dominari (DOMH), Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "biotechnology" industry. Agenus vs. Achieve Life Sciences Lexicon Pharmaceuticals Regulus Therapeutics Dominari Fortress Biotech Curis Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Agenus (NASDAQ:AGEN) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings. Do analysts rate AGEN or ACHV? Agenus currently has a consensus price target of $8.75, indicating a potential upside of 433.54%. Achieve Life Sciences has a consensus price target of $15.75, indicating a potential upside of 430.30%. Given Agenus' higher possible upside, equities research analysts clearly believe Agenus is more favorable than Achieve Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Do institutionals & insiders have more ownership in AGEN or ACHV? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 4.6% of Agenus shares are owned by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, AGEN or ACHV? Achieve Life Sciences has lower revenue, but higher earnings than Agenus. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$103.46M0.40-$245.76M-$10.68-0.15Achieve Life SciencesN/AN/A-$29.82M-$1.23-2.41 Does the media favor AGEN or ACHV? In the previous week, Agenus had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 6 mentions for Agenus and 5 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.25 beat Agenus' score of 0.08 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Achieve Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, AGEN or ACHV? Agenus has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Is AGEN or ACHV more profitable? Achieve Life Sciences has a net margin of 0.00% compared to Agenus' net margin of -145.89%. Agenus' return on equity of 0.00% beat Achieve Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-145.89% N/A -85.68% Achieve Life Sciences N/A -108.30%-65.20% Does the MarketBeat Community believe in AGEN or ACHV? Agenus received 133 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 68.78% of users gave Agenus an outperform vote. CompanyUnderperformOutperformAgenusOutperform Votes46768.78% Underperform Votes21231.22% Achieve Life SciencesOutperform Votes33470.46% Underperform Votes14029.54% SummaryAchieve Life Sciences beats Agenus on 10 of the 18 factors compared between the two stocks. Remove Ads Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.51M$3.05B$5.74B$8.28BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-0.1530.1524.7219.36Price / Sales0.40460.58397.6793.27Price / CashN/A168.6838.1634.64Price / Book-0.214.347.154.51Net Income-$245.76M-$71.72M$3.20B$247.14M7 Day Performance-5.20%0.33%2.84%3.64%1 Month Performance-46.93%-7.37%6.99%-2.30%1 Year Performance-85.32%-20.93%15.59%4.93% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus3.5022 of 5 stars$1.67+1.8%$8.75+424.0%-85.0%$42.27M$103.46M-0.15440ACHVAchieve Life Sciences2.3387 of 5 stars$2.91+5.4%$15.75+441.2%-35.4%$100.93MN/A-2.5820LXRXLexicon Pharmaceuticals2.4591 of 5 stars$0.38+3.7%$3.67+864.9%-83.8%$93.32M$31.08M-0.51140RGLSRegulus Therapeutics2.474 of 5 stars$1.37-7.4%$12.75+830.7%-46.4%$90.72MN/A-1.2930Earnings ReportDOMHDominari2.1142 of 5 stars$4.92+4.5%N/A+131.6%$53.69M$12.59M-1.274News CoveragePositive NewsGap UpFBIOFortress Biotech2.1056 of 5 stars$1.74+4.2%$15.67+800.4%-11.1%$48.17M$62.50M-0.57170Upcoming EarningsNews CoverageCRISCuris2.5175 of 5 stars$2.98+4.9%$23.00+671.8%-75.9%$25.23M$10.26M-0.3860Upcoming EarningsBOLTBolt Biotherapeutics3.4731 of 5 stars$0.41-0.7%$3.50+751.6%-63.5%$15.73M$9.78M-0.2490Earnings ReportAnalyst ForecastNews CoverageGap DownSABSSAB Biotherapeutics2.4223 of 5 stars$1.63+1.0%$12.40+662.6%-67.2%$15.22M$2.24M0.00140Upcoming EarningsNews CoverageGap UpMTEMMolecular Templates1.0556 of 5 stars$0.00-80.0%N/A-100.0%$1,000.00$23.48M0.00260Upcoming EarningsGap DownAMGNAmgen4.1131 of 5 stars$317.63+1.3%$314.04-1.1%+13.8%$170.67B$33.42B42.0828,000Positive News Remove Ads Related Companies and Tools Related Companies Achieve Life Sciences Alternatives Lexicon Pharmaceuticals Alternatives Regulus Therapeutics Alternatives Dominari Alternatives Fortress Biotech Alternatives Curis Alternatives Bolt Biotherapeutics Alternatives SAB Biotherapeutics Alternatives Molecular Templates Alternatives Amgen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
